Intra-Cellular Therapies (ITCI) Misses Q4 EPS by 5c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q4 EPS of ($1.05), $0.05 worse than the analyst estimate of ($1.00). Revenue for the quarter came in at $25.7 million versus the consensus estimate of $25.37 million.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• Okta upgraded as AI security opportunity boosts outlook
• Fervo Energy Company (FRVO) Reports Q2 Loss of $0.38
• Arbutus Biopharma (ABUS) Reports In-Line Q2 EPS